ARTICLE | Clinical News
DCR-MYC: Phase I ongoing
May 25, 2015 7:00 AM UTC
Dicerna said the open-label, dose-escalation, U.S. Phase I trial of IV DCR-MYC will now include an expansion cohort of patients with advanced pancreatic neuroendocrine tumors (PNETs). The addition is ...